JAK2 and cancer: In subgroup analyses, SVRRs were not significantly influenced by reason for prior ruxolitinib failure (relapsed/refractory or intolerant), number of prior anti‐cancer therapies, platelet count, hemoglobin level, patient age, or JAK2 mutational status (Table 2).